Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.42 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994646 | 1.00 | CDK5 (0.49) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL536894 | 1.00 | CDK5 (0.49) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL17487194 | 0.87 | CDK5 (0.45) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL3869935 | 0.78 | SRD5A1 (0.38) | CDK5CDK5R1CYP19A1 | |
| SCHEMBL15121547 | 0.78 | SRD5A1 (0.38) | CDK5CDK5R1CYP19A1 | |
| SCHEMBL3869928 | 0.78 | SRD5A1 (0.38) | CDK5CDK5R1CYP19A1 | |
| SCHEMBL513488 | 0.77 | CDK5 (0.33) | CDK5CDK5R1NR1I3 | |
| SCHEMBL9066105 | 0.74 | CYP19A1 (0.61) | CYP19A1AKR1B10 | |
| SCHEMBL8079491 | 0.74 | SRD5A2 (0.37) | CYP19A1 | |
| SCHEMBL8079488 | 0.74 | SRD5A2 (0.37) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002047644-A1 | COMPOSITION COMPRISING 7-HYDROXY DHEA AND/OR 7-KETO DHEA AND AT LEAST A 5α-REDUCTASE INHIBITOR | L'OREAL (FR) | 2002-06-20 | — | — | WO | claimed |
| EP-0705272-B1 | NOVEL PROCESS FOR PREPARING 17 BETA-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | RICHTER GEDEON VEGYESZET (HU) | 2002-03-27 | — | — | EP | claimed |
| EP-0473226-B1 | Trialkysilyl trifluoromethanesulfonate mediated functionalization of 4-aza-5alpha-androstan-3-one steroids | MERCK & CO INC (US) | 1996-07-31 | — | — | EP | claimed |
| EP-0705272-A1 | NOVEL PROCESS FOR PREPARING 17 BETA-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1996-04-10 | — | — | EP | claimed |
| EP-0662977-A1 | NOVEL 17$g(b)-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1995-07-19 | — | — | EP | claimed |
| WO-1995000531-A1 | NOVEL PROCESS FOR PREPARING 17β-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1995-01-05 | — | — | WO | claimed |
| WO-1994007909-A1 | NOVEL 17β-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1994-04-14 | — | — | WO | claimed |
| US-7872135-B2 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2011-01-18 | — | — | US | disclosed |
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | SIEGFRIED LTD. (CH) | 2006-05-11 | — | — | US | disclosed |
| WO-2002047644-A1 | COMPOSITION COMPRISING 7-HYDROXY DHEA AND/OR 7-KETO DHEA AND AT LEAST A 5α-REDUCTASE INHIBITOR | L'OREAL (FR) | 2002-06-20 | — | — | WO | disclosed |
| EP-0705272-B1 | NOVEL PROCESS FOR PREPARING 17 BETA-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | RICHTER GEDEON VEGYESZET (HU) | 2002-03-27 | — | — | EP | disclosed |
| EP-0705272-B1 | NOVEL PROCESS FOR PREPARING 17 BETA-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | RICHTER GEDEON VEGYESZET (HU) | 2002-03-27 | — | — | EP | disclosed |
| US-5583138-A | REDUCTASE INHIBITOR; SKIN DISORDERS | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1996-12-10 | — | — | US | disclosed |
| EP-0662977-A1 | NOVEL 17$g(b)-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1995-07-19 | — | — | EP | disclosed |
| WO-1995000531-A1 | NOVEL PROCESS FOR PREPARING 17β-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1995-01-05 | — | — | WO | disclosed |
| WO-1995000531-A1 | NOVEL PROCESS FOR PREPARING 17β-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994007909-A1 | NOVEL 17β-SUBSTITUTED 4-AZAANDROSTANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR PREPARING SAME | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 1994-04-14 | — | — | WO | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0004949-B1 | 4-AZA-17-SUBSTITUTED-5-ALPHA-ANDROSTAN-3-ONE, THEIR A AND D HOMO ANALOGS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1983-09-21 | — | — | EP | disclosed |
| EP-0004949-A1 | 4-Aza-17-substituted-5-alpha-androstan-3-one, their A and D homo analogs, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100434-A1 | Method for introducing a 1,2-double bond into 3-oxo-4-azasteroid compounds | NR3C2, NR5A1, CYP11B1 | CDK5 3005/4885CDK5R1 749/4885NR1I3 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.